Rotablation in Patients with Advanced Renal Insufficiency through End-Stage Renal Disease: Short- and Intermediate-Term Results

Table 1

Demographic data and CAD vessel numbers in rotablation patients.

Variables	Group A	Group B	value
	(CR < 5 mg/dl)	(CR ≥ 5 mg/dl through ESRD)
	N = 338	N = 73
Sex (M/F)	221/117	48/25	0.952
Age (years)	75.2 ± 10.7	66.8 ± 11.4	<0.001
Clinical diagnosis (N, %)
Stable angina	67 (19.8%)	16 (21.9%)	0.472
Unstable angina	120 (35.5%)	27 (37.0%)
NSTEMI	76 (22.5%)	14 (19.2%)
STEMI	13 (3.8%)	1 (1.4%)
Ischemic CM	45 (13.3%)	11 (15.1%)
Cardiogenic shock	17 (5%)	4 (5.5%)
Hypertension (N, %)	249 (73.7%)	53 (72.6%)	0.852
Diabetes (N, %)	201 (51.0%)	40 (58.3%)	0.462
PAD (N, %)	32 (9.5%)	12 (16.4%)	0.081
Baseline LVEF (%)	45.9 ± 12.5	44.1 ± 13.1	0.335
Laboratory data
Hemoglobin (mg/dl)	11.6 ± 2.1	10.1 ± 2.0	<0.001
BUN (mg/dl)	35.5 ± 74.3	66.3 ± 24.6	0.013
CR (mg/dl)	1.6 ± 1.0	8.2 ± 2.3	<0.001
CKD-EPI eGFR (ml/min/1.73 m^2)	57.8 ± 28.2.2	6.5 ± 1.9	<0.001
Cholesterol (mg/dl)	150.1 ± 31.9	141.8 ± 32.9	0.078
HDL chol (mg/dl)	45.0 ± 13.7	42.6 ± 13.8	0.264
LDL chol (mg/dl)	87.1 ± 29.0	76.6 ± 23.8	0.014
FBS (mg/dl)	151.9 ± 85.8	149.8 ± 93.5	0.874
HbA1c (mg/dl)	6.8 ± 1.4	6.5 ± 1.5	0.318
Total CK (U/L)	199.9 ± 338.3	198.0 ± 289.5	0.967
CK-MB (U/L)	10.6 ± 11.9	14.3 ± 18.8	0.056
Troponin (ng/ml)	3.3 ± 9.2	5.6 ± 14.7	0.130
CAD vessel numbers
SVD (N, %)	79 (23.4%)	11 (15.1%)	0.415
DVD (N, %)	94 (27.8%)	17 (23.3%)
TVD (N, %)	107 (31.7%)	35 (47.9%)
Plus LM (N, %)	41 (12.1%)	7 (9.6%)
Prior CABG (N, %)	17 (3.3%)	3 (4.1%)

CABG, coronary artery bypass grafting; CAD, coronary artery disease; CM, cardiomyopathy; CR, creatinine; DVD, double-vessel disease; ESRD, end-stage renal disease; FBS, fasting blood sugar; LM, left main coronary artery; NSTEMI, non-ST elevation myocardial infarction; PAD, peripheral artery disease; STEMI, ST elevation myocardial infarction; SVD, single-vessel disease; TVD, triple-vessel disease.